Matrix-M clinical trials
How each study uses Matrix-M is sorted by a rule, right about nine times in ten. Readers can ask us to read every study one by one.Ask us to read each study
Approvals
The first approval found in each region, with its record
- United States
- Not in FDA's approval records
- European Union
- Not in EMA's list of EU-wide authorisations
From FDA's Drugs@FDA and Purple Book (through openFDA) and the European Medicines Agency, files of Sept 2026 and 27 Oct 2026. National approvals in Europe and other countries are not included. How this is worked out
How studies write it
Studies that test it under each name
Studies by the year they started
10 studies that test it; most in 2021 (2)
| Year | Studies |
|---|---|
| 2011 | 1 |
| 2014 | 1 |
| 2015 | 1 |
| 2017 | 1 |
| 2021 | 2 |
| 2022 | 1 |
| 2023 | 2 |
| 2024 | 1 |
By phase
A phase 1/2 study counts in both.
What it is tested for
Each study’s main condition, where its own words name it, so a study counts once.
Who runs them
Industry 4 · Other 6
University of Oxford (5) · Novavax (3) · National Institute of Allergy and Infectious Diseases (NIAID) (1) · Isconova AB (1)
Often tested with
Tested in the same studies.
Malaria Vaccines (4) · Epstein-Barr Virus gp350-ferritin Nanoparticle Vaccine with Saponin-based Adjuvant (1) · PFS25 (1)
Studies
Open first, then newest update. How each study uses Matrix-M is read from its arms, and is right about nine times in ten. Ask us to read each study. These are the studies that list it as an intervention; a search of ClinicalTrials.gov also finds studies that mention it only in a description, such as earlier treatment.
Testing it · 10
- A Phase 1 Study to Assess an Escalating Dose, Multi-prime Vaccination Schedule of R21/Matrix-M™CompletedPhase 1University of OxfordNCT06320535Written as R21/Matrix M™ (Group 1)
- Trial Evaluating the Immunogenicity and Safety of an Adjuvanted Epstein-Barr Virus (EBV) Glycoprotein 350 Vaccine in EBV-seronegative PersonsCompletedPhase 1/2National Institute of Allergy and Infectious Diseases (NIAID)NCT05683834Written as Matrix-M1 Adjuvant
- R21/Matrix-M in African Children Against Clinical MalariaActive, not recruitingPhase 3University of OxfordNCT04704830Written as R21/Matrix-M
- Assessment of Safety and Immunogenicity of R21/Matrix-M™ in African Children Living With HIVCompletedPhase 1University of OxfordNCT05385510Written as R21/Matrix-M™
- A Study to Determine if New Types of Malaria Vaccines Are Safe, Effective and Lead to Immunity in Kenyan AdultsTerminatedPhase 2University of OxfordNCT03947190Written as R21/Matrix-M
- Safety, Immunogenicity and ex Vivo Efficacy of Pfs25-IMX313/Matrix-M in Healthy Volunteers in Bagamoyo, Tanzania.TerminatedPhase 1University of OxfordNCT04271306Written as Pfs25-IMX313 (10ug)/Matrix-M (50ug)
- Safety and Immunogenicity Study to Evaluate Single- or Two-Dose Regimens Of RSV F Vaccine With and Without Aluminum Phosphate or Matrix-M1™ Adjuvants In Clinically-Stable Older AdultsCompletedPhase 2NovavaxNCT03026348Written as Matrix-M1 Adjuvant
- Study to Evaluate the Immunogenicity and Safety of an Ebola Virus (EBOV) Glycoprotein (GP) Vaccine in Healthy SubjectsCompletedPhase 1NovavaxNCT02370589Written as Matrix-M Adjuvant
- A(H7N9) VLP Antigen Dose-Ranging Study With Matrix-M1™ AdjuvantCompletedPhase 1/2NovavaxNCT02078674Written as Matrix-M1™ adjuvant
- Study of Parenterally Administrated Adjuvanted Seasonal Influenza Vaccine in Healthy Elderly VolunteersStatus unknownPhase 1Isconova ABNCT01444482Written as Matrix M
Given beside what is tested · 2 — Matrix-M is usual care or a partner of the new treatment
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 Combined With R21/Matrix-M (a "Multi-stage" Malaria Vaccine)Active, not recruitingPhase 1University of OxfordNCT06958198Written as Matrix-M™
- A Study to Assess the Experimental Malaria Vaccines R78C and RH5.1 With Matrix-M in Combination With R21/Matrix-MActive, not recruitingPhase 2University of OxfordNCT07183371Written as Matrix-M™
Codes
What other systems call Matrix-M · ClinicalTrials.gg INT000865
- MeSH (NLM) C000625666Matrix-MOne source ClinicalTrials.gov
- UNII (FDA) YZ7P8Y8ECXMATRIX-M1 ADJUVANTOne source FDA
| System | Code | Name there | Checked by |
|---|---|---|---|
| MeSH (NLM) | C000625666 | Matrix-M | One source ClinicalTrials.gov |
| UNII (FDA) | YZ7P8Y8ECX | MATRIX-M1 ADJUVANT | One source FDA |
“Confirmed” means two independent publishers link the code to this drug; “one source”, one does and its name agrees.